Abiopharma

🔍 Schaeffer Orlov S Nicole (Executive)

Company: INSMED Inc (INSM)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 5,293 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 41,754.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 87,290 shares of Common Stock at $13.91 per share (Direct)
  Date: 2026-01-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 129,044.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 31,030 shares of Common Stock at $174.28 per share (Direct)
  Date: 2026-01-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 98,014.00 | transaction_form_type: 4 | Footnotes: F3, F4
• Sold 34,103 shares of Common Stock at $175.17 per share (Direct)
  Date: 2026-01-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 63,911.00 | transaction_form_type: 4 | Footnotes: F3, F5
• Sold 12,832 shares of Common Stock at $176.08 per share (Direct)
  Date: 2026-01-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 51,079.00 | transaction_form_type: 4 | Footnotes: F3, F6
• Sold 9,125 shares of Common Stock at $177.17 per share (Direct)
  Date: 2026-01-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 41,954.00 | transaction_form_type: 4 | Footnotes: F3, F7
• Sold 200 shares of Common Stock at $177.78 per share (Direct)
  Date: 2026-01-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 41,754.00 | transaction_form_type: 4 | Footnotes: F3, F8
• Acquired 27,600 shares of Stock Option (right to buy) at $177.12 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-02 | equity_swap_involved: 0 | shares_owned_after: 27,600.00 | transaction_form_type: 4 | Footnotes: F9
• Sold 87,290 shares of Stock Option (right to buy) at $13.91 per share (Derivative)
  Date: 2026-01-02 | Code: M | Expires: 2029-01-03 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F10

Footnotes:

• F1: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested.
• F2: Each RSU was granted on January 2, 2026 for no consideration.
• F3: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 29, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
• F4: This is the weighted average sales price representing 31,030 shares sold at prices ranging from $173.67 to $174.66 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
• F5: This is the weighted average sales price representing 34,103 shares sold at prices ranging from $174.67 to $175.65 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
• F6: This is the weighted average sales price representing 12,832 shares sold at prices ranging from $175.67 to $176.62 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
• F7: This is the weighted average sales price representing 9,125 shares sold at prices ranging from $176.68 to $177.67 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
• F8: This is the weighted average sales price representing 200 shares sold at prices ranging from $177.72 to $177.84 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
• F9: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested.
• F10: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.